Revenue crosses INR 2,500 crores, with strong earnings growth, EPS up 25%
- FY24 Revenue up by 12.3% YoY, crosses INR 2,500 crores
- FY24 EBITDA up 28.6%, and PAT up by 26.5% YoY
- FY24 EBITDA% up by 286 bps, and PAT% up by 146 bps YoY
MUMBAI, 30 MAY, 2024 (TGN): Consolidated Financial Highlights for the Financial Year 2023-24 (In INR Mn)
| Particulars | March 31, 2024 | March 31, 2023 | YoY Growth |
| Revenue from operations | 25,896 | 23,061 | 12.3% |
| Revenue from operations ($ Mn) | 312.8 | 287.5 | 8.8% |
| EBITDA | 5,841 | 4,542 | 28.6% |
| Profit before tax | 4,586 | 3,630 | 26.3% |
| Profit after tax | 3,367 | 2,661 | 26.5% |
Consolidated Financial Highlights for the Quarter ended March 31, 2024
(In INR Mn)
| Particulars | Q4FY24 | YoY Growth | QoQ Growth |
| Revenue from operations | 6,730 | 6.5% | -0.1% |
| Revenue from operations ($ Mn) | 81.1 | 5.2% | 0.1% |
| EBITDA | 1,643 | 48.7% | 1.4% |
| Profit before tax | 1,336 | 68.7% | 1.0% |
| Profit after tax | 949 | 94.6% | -3.9% |
Manish Gupta, Chairman and Chief Executive Officer – “We are pleased with our continued performance this quarter and the full year. Today in the marketplace we are known as a digital first commercialization partner to the global life sciences industry. We have 63 active clients and work with all the top 20 global pharmaceutical companies. Our revenues very closely mirrors the global life sciences industry’s spends on operations. 69% of our revenues come from the top 20 Pharma companies. Global Life Sciences industry is more than USO 1.8 Tn Industry. We are excited about the opportunity in front of us.”
Suhas Prabhu, Chief Financial Officer – “Our financial results reflect our focus on operational excellence, cost optimization and value-driven service delivery. While revenue grew steadily, we delivered strong growth in margins, with a healthy cash conversion and a strong balance sheet, providing us with the flexibility to invest in growth opportunities. We remain committed to delivering value to our clients and shareholders through deep domain expertise, innovation and operational excellence.”
About lndegene:
lndegene Limited (BSE: 544172, NSE: INDGN) is a digital-first, life sciences commercialization company. We help biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. We bring together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions. These aim to deliver, amongst other outcomes, a personalized, scalable and omnichannel experience for patients and physicians. It’s what drives our team and our purpose to enable healthcare organizations to be future ready.
